• health-prof-011
  • Information Sheets
  • Member resources
  • AMS Congress 2014

Women generally undergo menopause between the ages of 45 and 55 years. Around the time of menopause many women may experience symptoms such as hot flushes, sweats, vaginal dryness, loss of libido, irritability, sleep disturbance, and muscle/joint pains. There are a number of ways of managing these symptoms, but for those whose symptoms are troublesome and disruptive, oestrogen containing HRT may be considered.

The following advice does not apply to 'bio-identical', lozenge or compounded hormone products. There are inadequate safety or efficacy data for these products and they should be avoided. 

 pdfMenopause - oestrogen only therapy May 2012619.4 KB

Types of hormone therapy (HRT) 

  • Women who have not had a hysterectomy are advised to take combined hormone replacement therapy (HRT) which contains oestrogen plus progestogen. The progestogen protects the endometrium against hyperplasia or cancer and does not have a therapeutic role.
  • After hysterectomy HRT only needs to contain oestrogen.
  • Young women who have had their ovaries and uterus removed may consider additional testosterone therapy..
  • Women with vaginal dryness causing discomfort should consider vaginal oestrogen treatment.

How the Oestrogen-only hormones are taken

  • Oestrogens are available as tablets, skin patches and gels.
  • The products contain different kinds of oestrogen (oestradiol, conjugated equine oestrogen or oestriol) which are all thought to be effective in treating menopausal symptoms
  • There is no clear consensus about which delivery method is best.
  • Patches or gels are better for those who have high triglyceride concentrations, are at increased risk of DVT (deep vein thrombosis) – including those with hypertension, overweight or smokers, and those who may not absorb tablets adequately. (See Menopausal Treatments and the Risk of Blood Clots).
  • Vaginal oestrogen in creams, pessaries or tablets is available for women with symptomatic vaginal dryness.

The benefits of Oestrogen

  • Oestrogen reduces the severity and frequency of hot flushes by around 85%.
  • Oestrogen improves vaginal dryness.
  • By reducing menopausal symptoms, oestrogen may improve sleep and quality of life.
  • Oestrogen reduces the risk of post-menopausal bone fracture, including hip fracture. Oestrogen increases bone density.
  • Oestrogen use is not associated with weight gain

Side-effects of oestrogen-only HRT

  • Common side-effects, which are usually temporary, include breast enlargement and tenderness, and nausea. This may be dose related.

The risks of oestrogen-only HRT

  • Oestrogen should be prescribed for the relief of troublesome menopausal symptoms.
  • Women who go through menopause before 45 years are usually advised to take oestrogen until the age of average menopause at 50 years. The decision to continue oestrogen beyond 50 should be reviewed annually by the woman in consultation with her doctor. (See AMS pamphlet on Early Menopause)
  • Oestrogen increases the risk of blood clots (venous thromboembolism). The risk increases with age and other risk factors such as obesity, previous thromboembolism, smoking and immobility. In low-risk women less than 60 years the risk is low. The risk may be less with the use of oestrogen gel or skin patches.
  • Oral oestrogen increases the risk of stroke and the risk increases with age. Stroke risk is not significantly altered in women younger than 60 years with normal blood pressure. The risk may be less with lower doses and the use of oestrogen gel or skin patches.
  • Oral oestrogen is associated with an increased risk of gallbladder inflammation (cholecystitis). There is no data regarding gel or skin patches.
  • Oestrogen alone does not appear to increase the risk of breast cancer
  • Oestrogen alone commenced at the time of menopause does not increase the risk of coronary heart disease and may decrease the risk.
  • See separate graphs of Risks and Benefits of HRT from WHI Study in AMS pamphlet list

Managing the risks

  • HRT should not be prescribed unless mammographic screening is up to date
  • Regular breast checks and screening mammograms should be performed in women over 50 years.
  • A decision to use oestrogen should be reviewed annually by the woman in consultation with her doctor. Personal benefits versus risk should be discussed.
  • Oestrogen is not a first line treatment for fracture prevention. However, some women may elect to use hormone therapy to protect against osteoporosis- this needs to be done in consultation with the woman's doctor and the woman needs to understand the risks and benefits of this therapy.
  • If a woman using oestrogen develops symptoms suggesting a DVT or stroke she should stop the HRT and seek medical attention. (See Menopausal Treatments and the Risk of Blood Clots)


This fact sheet is designed to be informative and educational.
 It is not intended to provide specific medical advice or replace advice from your health practitioner.


AMS New directions in women's health 

Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person's circumstances and should always be discussed with that person's own healthcare provider.

This Information Sheet may contain copyright or otherwise protected material. Reproduction of this Information Sheet by Australasian Menopause Society Members and other health professionals for clinical practice is permissible. Any other use of this information (hardcopy and electronic versions) must be agreed to and approved by the Australasian Menopause Society.

Content update July 2012

What's New?


  • Menopause Management

    AMS provides information for doctors and other health practitioners in supporting women through midlife health and the menopause. The Information Sheets have been organi...
  • Calcium Supplements – a patient guide *New

    The use of calcium supplements has long been considered an integral part of managing osteoporosis, with detailed reviews of medical research indicating a reduction in fra...
  • AMS Guide to Equivalent HRT Doses

    This Information Sheet has been developed as a guideline only to approximately equivalent doses of the different HRT products available in 2014. The intention is to help ...
  • Complementary and Herbal Therapies for Hot Flushes

    Many women experience hot flushes and night sweats around the time of menopause. Hormone replacement therapy (HRT) has been proven to be effective in alleviating these sy...


  • Postmenopausal cancer highlighted

    World Menopause Day 18 October, 2013: The International Menopause Society is marking World Menopause Day with the publishing of a major review of cancer during and after...
  • Menopause on the ABC HealthOnline

    Menopause has had a resurgence of interest in the media lately with a series of articles posted on the ABC HealthOnline: Riding the menopause rollercoaster  Horm...
  • A woman's rite in Active Retirees

    The June - July 2013 edition of the Probus magazine Active Retirees featured menopause as the health article. Author Simone McClenaughan extensively interviewed AMS Pres...
  • Global Consensus Statement on MHT - IMS media release

    March 15, 2013: International Menopause Society - Media release An international meeting of organisations working in menopause and women’s health has concluded Menopaus...